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Abstract
Hepcidin is a small peptide with a critical role in cellular iron homeostasis, as it regulates utilization of stored iron and antimicrobial defense in in-
flammation (bacterial and fungal). Since it was isolated in 2000, and especially in the last decade, numerous studies aimed to evaluate the clinical 
use of plasma and urine hepcidin as a marker of anemia, especially anemia of chronic disease and post-transplant anemia (PTA). Hepcidin regulati-
on is delicately tuned by two inflammatory pathways activated by interleukin-6 (IL-6) and bone morphogenic proteins (BMPs) and iron regulated 
pathway sensitive to circulating transferin-iron (TR-Fe) complex. BMP-mediated pathway and TR-Fe sensitive pathway seem to be connected by 
hemojuveline, a BMP co-factor that interacts with transferine receptor 2 (TRF2) in cases of high TR-Fe circulatory concentration. In addition to these 
regulatory mechanisms other regulators and signaling pathways are being extensively researched.
Hepcidin has been identified as an important contributor to morbidity and mortality in end stage renal disease (ESRD) but no such association has 
jet been found in case of PTA. However, there is an association between higher doses of erythropoiesis-stimulating agents (ESA) and mortality in the 
posttransplant period and the assumption that hepcidin might play a role in ESA resistance in PTA. Thus the review’s main goal was to summarize 
papers published on the association of hepcidin with PTA, give up-to-date information on hepcidin regulation and on potential therapeutics that 
optimize hepcidin regulation. We also compared the performances of tests for hepcidin determination and reviewed research on immunosuppres-
sants’ (IS) effect on hepcidin concentration. 
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We reviewed all studies accessed by literature 
search of PubMed and SCOPUS from January 2000 
to January 2015. The terms used as key words for 
the search were “hepcidin kidney transplantation” 
and “hepcidin post-transplant anemia”. Additional 
papers were included after revision of reference 
lists in the found papers. Acquired data covers 
hepcidin physiology - regulatory pathways of hep-
cidin synthesis, isoformes of hepcidin and proteins 
that bind hepcidin in the circulation, as well as the 
role of kidneys in hepcidin excretion. Changes in 
hepcidin concentration after renal transplantation 
(TX) and their clinical significance could be useful 
to nephrologists and other clinicians involved in 
the management of renal transplant recipients. On 
the other hand, specialists in laboratory medicine 
could benefit from a systematic review of all avail-
able methods used for hepcidin determination in 
plasma and urine and data on their precision and 
analytical recovery that we collected. We also gave 
possible reasons for different hepcidin reference 
values reported using different methods. Re-
searchers in pharmaceutical industry could be in-
terested in mechanisms that were reported to 
lower hepcidin and possibly lead to the develop-
ment of therapeutics that target hepcidin regula-
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tion. Finally, nutritionists could benefit from meas-
urement and monitoring of hepcidin in studies as-
sessing nutritional vs. iron substitution therapy 
where closer iron absorption is necessary. In this 
article we tried to address the contribution of high 
hepcidin concentration to post-transplant anemia 
(PTA), the possible relationship between hepcidin 
and other markers of iron status and glomerular 
filtration rate (GFR) after renal TX, the alteration of 
hepcidin concentration depending on the type of 
IS used after renal TX, the association between 
hepcidin and prohepcidin in the circulation; the 
differences in performances of tests for hepcidin 
determination and their current standardization. 
Physiology of hepcidin
Biosynthesis and processing of hepcidin
Hepcidin is a 25 amino acid (aa) peptide that regu-
lates iron release from its stores. Krause et al. iso-
lated hepcidin from human blood ultrafiltrate in 
the year 2000 and detected it as a cistein rich pep-
tide with molecular mass of 2789.8 Da on matrix 
assisted laser desorption ionization-time of flight 
mass spectrometry (MALDI-TOF MS) (1). It is pre-
dominantly synthesized in the liver. Low levels of 
hepcidin expression have also been detected in 
various human organs, such as heart, brain, gas-
trointestinal tract, bladder, lungs, glands, skeletal 
muscle and kidneys (Table 1). Immunohistochemi-
cal studies of liver biopsy samples using various 
region specific antibodies enabled the localization 
of hepcidin on the basolateral membranes of 
hepatocytes in periportal zones, with their con-
centration decreasing from portal triads towards 
central veins. There, hepcidin cDNA is translated to 
Tissue Expression of 
hepcidin gene*
Stomach, duodenum, bladder, thyroid 
gland, adrenal gland, prostate gland, 





Gene expression was measured using real-time quantitative 
polymerase chain reaction (RT-PCR). Hepcidin expression 
for each tissue was divided by the value of glyceraldehyde-
3-phosphate dehidrogenase (GAPDH) housekeeping gene and 
standardized by kidney expression (1-fold expression).
Table 1. Expression of the hepcidin gene in different tissues (1). 
84 aa preprohormone with 24 aa signal peptide at 
the N terminal. After cleavage of the signal pep-
tide, a 60 aa prohepcidin is formed, which is a pro-
hormone without biological activity. Prohepcidin 
is converted to active hepcidin in plasma by con-
vertases in blood or liver capillaries wall cells. It is 
possible that hepcidin-25 undergoes some N-ter-
minal cleavage that results in the production of 
two smaller isoforms (hepcidin-20 and -22), or that 
these isoforms are products of prohepcidin cleav-
age by convertase. All isoforms of hepcidin are ex-
creted in urine. Peptide sequence of human hepci-
din is shown in Figure 1 (2). 
Metabolic role of hepcidin
Like hepcidin-25, hepcidin-22 is an antimicrobial 
agent (in vitro), but the biological significance of 
hepcidin-20 is unknown. Active hepcidin has an 
immune and iron-regulatory role. Immunological-
Figure 1. Amino acid sequence of hepcidin precursors and 20-, 22- and 25-hepcidin peptides (2).
Vertical dashed lines denote cleavage sites resulting in different peptide forms. 
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ly, hepcidin is consistent with type II acute phase 
proteins and three inflammatory mediators are 
needed for its induction in hepatocytes – IL-6, 
BMP6 and activin B. Immunological activation of 
hepcidin gene (HAMP – hepcidin antimicrobial 
peptide) transcription was first discovered in 
hepatocytes as a reaction to pro-inflammatory IL-
6, but similar activation was detected in mono-
cytes. In monocytes incubation with IL-6 and 
interferon-γ (INFγ) increased hepcidin mRNA in a 
dose-dependent manner, 10-fold higher than in 
control hepatocyte cultures (HepG2 cells), as well 
as faster (peak induction of hepcidin mRNA in 
monocyte was at 1 hour of incubation and in 
HepG2 cells at 3 - 6 hours) (3). Higher hepcidin 
plasma concentrations in pro-inflammatory milieu 
are needed for protective reasons. In bacterial in-
fection hepcidin “hides” iron in its stores from bac-
teria that have high-affinity iron-binding sidero-
phores for retrieving iron from hosts’ transferrin 
and using it for their optimal growth and metabo-
lism. It also kills bacteria on contact, like other de-
fensin proteins (4). It is possible that in the same 
way elevated hepcidin makes it harder for cancer 
cells to get the iron they need for their growth (5). 
Hepcidin’s iron-regulatory function consists in dis-
abling the passage of stored iron from enterocytes 
into the duodenum; and from hepatocytes and 
macrophages into the circulation. This is achieved 
by hepcidin’s binding to the iron channel ferropor-
tin. Ferroportin is the only iron exporter in these 
iron storage cells and it is rapidly degraded after 
hepcidin’s binding (6). After ferroportin degrada-
tion, the retained iron is “trapped” in cytoplasmic 
ferritin form and unavailable to be used for eryth-
ropoesis. 
Use of radiolabeled 125I-hepcidin revealed that 
about 90% of hepcidin circulates bound to α2-
macroglobulin (specific binding) and the rest is 
bound to albumin (nonspecific binding with non-
saturable kinetics) or unbound. Hepcidin bound to 
α2-macroglobulin seems to be active – it was 
found to decrease ferroportin expression in cell 
culture (7). The recent study by Huang et al. 
showed that serum iron levels are reduced to a 
significantly greater extent in mice treated with 
α2-macroglobulin-hepcidin complex than in those 
treated with unbound hepcidin. The researchers 
suggested that this binding delays hepcidin excre-
tion by the kidney and increases its circulatory 
half-life and efficacy compared to free hepcidin 
(unbound 125I-hepcidin was significantly increased 
in the kidney and urine relative to 125I-hepcidin 
complexed to α2-macroglobulin) (8). 
Regulation of hepcidin activity
Although hepcidin peptide was isolated in 2000, 
HAMP gene was not discovered until two years lat-
er, in 2002 by Nicolas et al., on chromosome 19 
(NCBI Gene ID 57817) (9). An inflammatory trig-
gered pathway includes IL-6 that binds to IL-6 re-
ceptor (IL-6-R) and activates Janus kinase 2/signal 
transducer and activator of transcription 3 (JAK2/
STAT3) signaling to up-regulate HAMP. This activa-
tion was also observed in cultures of primary hu-
man hepatocytes from micro-inflamed ESRD (10). 
Very intensively studied inflammatory pathways 
include members of transforming growth factor-β 
(TGF-β) superfamily (BMPs 2, 4, 5, 6, 7 and 9) that 
were found to induce BMP signaling by phospho-
rilation of Sma and Mad related proteins (SMADs). 
Most of the data was collected on BMP6, which to-
gether with activin B binds to bone morphogenic 
protein receptor (BMP-R) and phosphorilates cyto-
plasmic SMAD1, 5 and 8 proteins that, together 
with SMAD4, translocate to the nucleus and stimu-
late hepcidin expression by interaction with BMP 
responsive elements on HAMP promoter (11,12). In 
Bmp6 disrupted mice hepcidin expression was so 
low that it led to iron overload which could not be 
compensated by other BMPs. Membrane hemoju-
velin (mHJV) was identified as a BMP co-receptor 
in this pathway. Homozygotes or combined hete-
rozygotes mutations of glycophospatidylinositol- 
(GPI-) anchored mHJV in humans markedly reduce 
hepcidin expression and cause juvenile hemo-
chromatosis. This mHJV is an important factor in 
the iron regulatory pathway of hepcidin expres-
sion and represents itsconnection to BMP-SMAD 
pathway. When TR-Fe complex concentrations in-
crease in the circulation, like in hemochromatosis, 
it binds to transferring receptor 1 (TRF1) and dis-
places hereditary hemochromatosis protein (HFE) 
and signals HAMP induction, possibly through in-
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teraction with TFR2. Hepcidin regulation by HFE, 
which interacts with TFR2 and mHJV to form a “su-
percomplex” and leads to up-regulation of hepci-
din expression via BMP-SMAD signaling, is still not 
entirely clarified. Use of tagged proteins showed 
“supercomplex” formation in cell cultures, but 
their interaction has not been shown in vivo (in 
mice and humans) and the precise molecular 
mechanism of HFE and TRF2 role in hepcidin regu-
lation is still under investigation (13). Matriptase-2 
(MT-2) is a membrane protease in hepatocytes that 
acts as a hepcidin suppressor and inhibits the “su-
percomplex” formation. MT-2 was tested in human 
and animal models and it was found that MT-2 
mutations cause high hepcidin expression and 
iron deficiency anemia refractory to therapy. MT-2 
cleaves mHJV in hepatocytes and mHJV cannot 
act as a BMP co-receptor. Neogenin is a ubiquitous 
cell surface protein that forms a tertiary complex 
with MT-2, BMP receptor and HJV thus facilitating 
MT-2 mediated HJV cleavage. It was found to be 
essential for HJV function in mice, but this is still to 
be confirmed in humans (14). Another hepcidin 
up-regulating mechanism appears to be activated 
by endoplasmatic reticulum stress, which activates 
hepcidin promoter gene through the cyclic aden-
osine monophosphate (cAMP) response element-
binding protein H (CREBH), a liver-specific tran-
scription factor (15). It physiologically prevents iron 
utilization and iron overload; his down-regulation 
was first documented in iron overload disorders - 
most forms of hereditary hemochromatosis (16-19) 
and later in cases of thalassemia (20). Except he-
reditary causes for hepcidin down-regulation, 
such as HFE mutations in hereditary hemochroma-
tosis and mHJV mutation in juvenile hemochro-
matosis, the most specific evidence on hepcidin 
suppression were found for MT-2. Other studies 
identified hypoxia-inducible factors (HIF), HIF-1α 
and HIF-2α, which presumably have a role in 
down-regulation of hepcidin in hypoxia. They 
bind to enhancer element of erythropoietin (EPO) 
gene and activate its transcription (21). A study on 
hepatocyte cultures showed that proteolytic 
cleavage of prohepcidin to hepcidin is not regulat-
ed by TR-Fe complex or the HIF pathway (22). Two 
other research groups found that hepcidin expres-
sion was not directly regulated by HIFs (23,24). 
Thus the effect of HIFs on hepcidin down-regula-
tion is still controversial. One study found that 
hepatocyte mHJV was elevated only in chronic 
kidney disease (CKD) patients undergoing hemo-
dialysis (HD), not in renal transplant recipients or in 
CKD patients who weren’t treated with HD. In this 
study each of the 3 patient’s groups had only 31 
patients (25). Molecular mechanisms responsible 
for the increase in hepcidin concentrations in hy-
poxia are yet to be clarified. Several studies 
showed that the induction of erythrocytopoesis 
causes down-regulation of hepcidin, and not hy-
poxia or anemia. In cases of bone marrow suppres-
sion by citotoxic agents or irradiation, the down-
regulation of hepcidin does not occur (26,27). Fur-
thermore, when EPO was subcutaneously admin-
istered to healthy humans, hepcidin was pro-
foundly suppressed in the next 24 hours (and 
gradually recovered during the following two 
weeks), while soluble transferrin receptor and 
growth differentiation factor-15 (GDF15) remained 
constant (28). Ashby et al. examined few candi-
dates for bone marrow-derived mediators of hep-
cidin suppression. EPO was considered to lead to 
hepcidin suppression by reducing transferrin satu-
ration, but hepcidin decrease in serum precedes 
the reduction in transferrin saturation (29). A study 
performed on freshly isolated mice hepatocytes 
and human hepatocytes (cell line HepG2) showed 
that hepcidin mRNA was down-regulated by EPO, 
administered in supraphysiological, therapeutic 
doses, in a dose-dependent manner. This effect 
was blocked by anti-EPO receptor (anti-EPO-R) an-
tibody, along with a down-regulation of CCAAT/
enhancer-binding protein α gene (CEBPA gene) 
mRNA that is responsible for expression of signal-
ing protein C/EBPα (CCAAT/enhancer-binding pro-
tein α). Protein C/EBPα binds to HAMP promoter 
and directly reduces hepcidin expression as a 
downstream result of EPO binding to EPO-R on 
hepatocyte surface (30,31) (Table 2). Schematic 
representation of hepcidin regulation pathways 
can be found in Figure 2.
Lakhal et al. showed that infusion of iron chelator 
deferoxamine increases plasma GDF15 in vivo, but 
the finding was limited by small number of partici-
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pants (8 healthy volunteers) and the increase was 
modest compared to in vitro responses in human 
cell lines. They investigated GDF15 further and in a 
study with slightly larger number of subjects (21 
iron-replete and 22 iron-deficient) found that 
GDF15 was higher in iron-deficient subjects. 
GDF15 is a BMP antagonist, but was not elevated 
in healthy subjects, iron deficiency or reduced 
hepcidin expression by blood loss (32).
Hepcidin in renal transplant recipients
The role of hepcidin in pathogenesis of anemia 
and its significance as biomarker of anemia
The European TRESAM Survey published in 2003 
reported anemia prevalence of 38.6%, and very 
similar prevalence of 42% was reported in 10 Euro-
pean centers in 2010 (33,34). This makes anemia 
more prevalent in kidney transplant patients than 
in GFR-matched CKD-patients. PTA shows two 
peaks. The early peak (within 3 months after TX) 
occurs because of low pre-transplant hemoglobin 
(Hb), blood loss or infection during surgery, ag-
gressive hydration or frequent blood sampling af-
ter surgery, delayed graft production of EPO and IS 
therapy influence (35). The late peak is associated 
with a decline in kidney function (36-38).
Hepcidin is predominantly produced in liver upon 
iron overload, hypoxia and inflammation, but kid-
neys are also involved in the synthesis of hepcidin, 
as well as in its elimination. Thus hepcidin concen-
trations are influenced by kidney graft function 
and post-transplant iron status. Hepcidin synthesis 
is up-regulated in uremia as in other inflammatory 
Regulator Mechanism of regulation Result
BMP Binds to BMP receptors on hepatocytes SMAD-mediated induction of HAMP transcription
mHJV Acts as a BMP co-receptor on hepatocytes Increases signal for SMAD-mediated HAMP transcription
sHJV Competes with HJV for BMP Decreases signal for SMAD-mediated HAMP transcription
MT-2 Cleavage of HJV on hepatocytes Inhibits BMP and SMAD-mediated HAMP transcription
IL-6 Binds to IL-6 receptor on hepatocytes Activates JAK2/STAT3-dependent signal pathway to promote HAMP transcription
TR-Fe Binds to transferin receptor 1 or 2 on hepatocytes Activates ERK 1/2-mediated HAMP transcription
HFE Binds to transferin receptor 1 and 2 on hepatocytes (competes with TR-Fe) Inhibits activation of ERK 1/2-mediated HAMP transcription
Endoplasmatic 
reticulum stress Activates CREBH in hepatocytes CREBH binds and activates HAMP promoter gene
EPO Binds to EPO-R on hepatocytes Deactivates CEBPA transcription and decreases C/EBPα-mediated activation of HAMP promoter
HIF Binds to enhancer elements of EPO and HAMP genes
Activates transcription of EPO and deactivates transcription 
of HAMP. Reduces hepcidin (?)
Activin B Activates SMAD signaling pathway in hepatoma-derived cell cultures
Contributes to inflammatory SMAD-mediated HAMP 
transcription in vivo (?)
GDF15 Induces changes in SMAD (?) Decreases SMAD-mediated HAMP transcription (?)
TWSG1 Blocks BMP signaling pathway Decreases SMAD-mediated HAMP transcription (?)
BMP – bone morphogenic protein; HAMP – hepcidin gene; mHJV – membrane hemojuvelin; sHJV – solubile hemojuvelin; MT-2 - 
matriptase-2; IL-6 – interleukin 6; JAK2/STAT3 - Janus kinase 2/signal transducer and activator of transcription 3; TR-Fe - transferin-iron 
complex; ERK 1/2 – extracellular-signal-regulated kinase 1/2; HFE - hereditary hemochromatosis protein; CREBH - cAMP response 
element-binding protein H; EPO-R – erythropoietin receptor; CEBPA – CCAAT/enhancer-binding protein α (C/EBPα) gene;  HIF – 
hypoxia indcibile factor; GDF15 – growth differentiation factor 15; TWSG1 – twisted gastrulation 1.
Table 2. Molecular regulation of hepcidin transcription (15,31). 
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Figure 2. Regulation of hepcidin antimicrobial peptide (HAMP) expression. 
Iron abundance (high Fe) induces bone morphogenic proteins (BMPs) binding to their receptor (BMP-R) and SMAD-mediated in-
duction of HAMP. Membrane hemojuvelin (mHJV) is a BMP co-receptor. Matriptase-2 (MT-2) is active in iron deficiency and hypoxia, 
inhibits BMP signal transmission. Solubile hemojuvelin (sHJV) is cleaved from HJV by furine convertase or type II transmembrane se-
rin protease TMPRSS6. It competes with sHJV in BMP and has a negative effect on BMP signal transmission. High iron concentration 
causes binding of transferring-iron complex (TR-Fe) to transferrin receptor 1 (TfR1). This binding displaces hereditary hemochroma-
tosis protein (HFE) and signals HAMP induction, through interaction with transferrin receptor 2 (TfR2) and extracellular-signal-regu-
lated kinases 1/2 (ERK1/2) signal pathway. 
Inflammation stimulates hepcidin production trough two mediators, interleukin-6 (IL-6) and activin B. IL-6 binds to IL-6 receptor (IL-
6-R) on hepatocyte and activates Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT 3) signal pathway. Ac-
tivin B binds to BMP-R and activates SMADs. Both inflammatory mediators have a positive effect on HAMP expression. Anemia causes 
an increase in production of erythropoietin that binds to erythropoietin receptor (EPO-R) and down-regulates expression of signal-
ing protein CCAAT/enhancer-binding protein α (C/EBPα) and hepcidin. The mechanisms of hypoxia inducible factor (HIF), growth dif-
ferentiation factor 15 (GDF15) and twisted gastrulation (TWSG) as HAMP modulators is still controversial.
states. Przybylowski et al. conducted a well de-
signed study including 170 renal allograft recipi-
ents and 168 patients after orthotopic heart TX, 
with very similar IS therapy used and no signs of 
inflammation or rejection. The prevalence of PTA 
was 37% among kidney transplant patients and 
34% among heart transplant patients. Anemic kid-
ney transplant patients, as well as anemic heart 
transplant recipients, exhibited significantly high-
er hepcidin when compared to their non-anemic 
counterparts. Based on their results it seems that 
the observed PTA and impaired kidney function 
(also present after heart TX), and not inflamma-
tion, were the leading causes of hepcidin elevated 
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concentrations since eGFR and ferritin, but not 
hsCRP were found to be predictive of hepcidin 
concentrations (39). Interestingly, the authors con-
cluded that it was plausible that hepcidin is not a 
pathogenic factor for PTA among heart or kidney 
transplant recipients. The role of hepcidin in 
pathogenesis of anemia of chronic disease is very 
well documented, especially in ESRD, since it is an 
important contributor to morbidity and mortality 
in ESRD. 
The role of hepcidin in resistance to 
erythropoiesis-stimulating agents (ESA) 
after renal transplantation (TX)
High plasma hepcidin concentrations decrease 
iron availability to bacteria and cancer cells lead-
ing to anemia of chronic disease, despite the ther-
apy with ESA (e.g. cancer, autoimmunity or chronic 
infection) (40). A functional iron deficiency can be 
often observed in renal transplant recipients – iron 
stores are adequately filled (normal or high ferritin 
levels and transferrin saturation at 20% or less), 
but iron is unable to be released from its stores, 
and subsequently erythrocytopoesis is inade-
quate. Since clinicians treat PTA with ESA, hepcidin 
could be used to clarify the often found disbal-
ance in iron metabolism and resistance to ESA in 
the post-transplant period. Therefore, hepcidin 
could become an important tool to predict ESA re-
sponsiveness and to guide treatment with ESA 
and intravenous iron. The prediction of ESA resist-
ance would be an important step forward in treat-
ing anemia after renal TX. Two cohort studies have 
reported an association between higher doses of 
ESA and mortality (41,42), as well as the results of 
randomized controlled trials that reported an in-
creased mortality or morbidity in patients who 
were targeted to high Hb concentrations (43,44). 
Hepcidin in relation to other biomarkers of 
anemia
Many studies showed an association between 
hepcidin and ferritin, either by correlation of the 
two parameters or ability of ferritin to predict hep-
cidin by multiple regression analysis. Indeed, hep-
cidin and ferritin have some common characteris-
tics – their plasma concentration is decreased in 
iron deficiency and increased in inflammation (but 
not specificaly, as they are both elevated in various 
cancers), and can be used in treating anemia after 
renal TX. In this sense, hepcidin shows some ad-
vantages over ferritin – it reflects iron availability 
and not just iron stores, and better reflects the sta-
tus of iron homeostasis than single parameters 
such as transferrin saturation, solubile transferrin 
receptors and CRP (45). A study was done by Kato 
et al. to evaluate hepcidin and prohepcidin as po-
tential predictors of ESA responsiveness in a small 
number of CKD patients on HD. Neither hepcidin 
nor prohepcidin were found to be good predic-
tors of ESA resposiveness (46). Besides the small 
number of subjects (only 75), the limitations of this 
study were that hepcidin was measured only sem-
iquantatively (peak intensity of serum hepcidin-25 
by SELDI-TOF MS). Multiple regression analysis did 
not show statistically significant association be-
tween prohepcidin and hematopoietic parame-
ters, but prohepcidin had a weak relationship with 
ESA dosage. The biggest disadvantage of using 
prohepcidin is that it is not an active form of hep-
cidin, and there is no clear relationship between 
prohepcidin and hepcidin concentration in circu-
lation, since available part of hepcidin degrades to 
iron-regulatory inactive isoforms (hepcidin-20 and 
-22). Malyszko et al. conducted a study that en-
rolled 70 subjects after renal TX and correlated 
hepcidin to other renal markers. Hepcidin was as-
sociated with total protein, creatinine, ferritin, 
eGFR (calculated by MDRD equation) and time af-
ter TX. Multiple regression analysis showed that 
only eGFR and ferritin could be considered as pre-
dictors of hepcidin. Since in healty subjects hepci-
din showed no association with creatinine and 
eGFR, it could be assumed that hepcidin is accu-
mulated in renal insufficiency CKD and could be 
used as a marker of it (47). The limitation of hepci-
din determination in this study was the determina-
tion by ELISA, which is not completely specific for 
hepcidin-25 (hepcidin-20 and -22 can also be 
measured). When compared to other markers of 
iron status, such as iron, ferritin and transferrin sat-
uration, hepcidin 25 seems to be the most sensi-
tive indicator of iron absorption. This is an indica-
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tion that in the future hepcidin could substitute 
conventional assays for measuring iron status. The 
only drawback is that hepcidin is limited to non-
inflammatory conditions, but this concerns also 
other tests for monitoring iron concentrations.
Elimination of hepcidin by kidneys
Since hepcidin is a very small peptide, it is filtered 
freely in the glomeruli and almost completely 
reapsorbed in the tubules (fraction extraction of 
hepcidin estimated in patients with hemochroma-
tosis and thalassemia was found to be less than 
3%) (48,49). Thus, it is clear that hepcidin is elimi-
nated by the kidneys, but it is still unclear which 
process is determining the rate of hepcidin elimi-
nation - filtration, reabsorption, local production 
and/or degradation. A study with limited number 
of participants has provided evidence that tubular 
reabsorption (via megalin-mediated endocytosis) 
and local production in distal kidney tubules may 
contribute to urine hepcidin concentrations. This 
production is stimulated by monocytes in inflam-
matory conditions, but monocytes are also capa-
ble of producing hepcidin, at least in cell cultures, 
when stimulated with pro-inflammatory cytokine. 
Furthermore, an increase of urine hepcidin-25 was 
considered a potential marker for tubular degra-
dation in patients with CKD since it seems to accu-
mulate in plasma and, according to Peters et al., it 
is due to inadequate tubular reabsorption in pa-
tients with biopsy proven tubular disease (similar 
observation was found earlier for prohepcidin by 
Taes et al.) (50,51). But the effect of uremia and 
how residual renal function determines hepcidin 
clearance is yet to be determined. Studies on a 
larger number of human subjects are necessary to 
confirm if inflammation after renal TX causes distal 
tubules and/or monocytes in kidney to produce 
hepcidin, determine the extent of this production 
and its clinical value. If local hepcidin production 
would prove to be valuable in monitoring the 
graft function, that would justify the determina-
tion of hepcidin concentrations in urine samples 
as markers of kidney inflammation and possibly 
predictors of post-transplant tubular degradation 
and renal rejection. 
Hepcidin and kidney disorders
As an acute phase protein, hepcidin is induced in 
inflammation. The subclinical inflammation often 
found in patients with CKD limits its use as a mark-
er of renal function. Since study by Peters at al. as-
sociated serum hepcidin with tubular degradation 
in CKD (hepcidin inversely correlated to eGFR), se-
rum and urine hepcidin was investifgated as a 
marker of acute kidney injury (AKI). Urinary hepci-
din was found to be a protective marker for AKI af-
ter cardiopulmonary bypass surgery. Interestingly, 
a smaller rise in hepcidin’s urine concentrations 
implied a greater renal injury (resulting in lesser 
hepcidin reabsorption from primary filtrate) and 
was associated with higher risk of AKI (52). Two pa-
pers published by Ho et al. found that increased 
urine hepcidin concentrations indicated lower risk 
of developing AKI after cardiac surgery, and this 
was confirmed in a larger study with 100 subjects. 
The increased local production of hepcidin in kid-
ney is attributed to the prevention of oxidative 
damage induced by free iron in AKI (hepcidin 
binds Fe2+) (53,54). It was found that in patients 
with lupus nephritis changes in urine hepcidin-25 
and -20 predict renal flares. Hepcidin-25 serum 
concentration decreased in a renal flare and hepci-
din-20 increased 4 months before a renal flare (this 
urine proteomics study was limited to 25 samples) 
(55). Lack of evidence regarding clinical signifi-
cance of urine hepcidin concentration after renal 
TX renders urine hepcidin use in monitoring con-
troversial. CKD is associated with increased serum 
hepcidin and it contributes to anemia and ESA re-
sistance. If ESA resistance could be predicted or 
even abolished by hepcidin monitoring or reduc-
tion, it would mean better management of CKD 
patients, and need for lower doses of ESA to cor-
rect anemia, since higher doses carry a risk of 
dose-related side effects. It seems that hepcidin 
reflects status of chronic (in CKD) and acute in-
flammation (in AKI), but by different mechanisms. 
In CKD hepcidin is up-regulated in the liver and in 
AKI presumably in the kidney, and therefore it is 
necessary for future research to measure hepcidin 
in serum and urine. Since hepcidin is an inflamma-
tory inducible peptide, it can only be used as an 
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indicator of renal function changes in cases of CKD 
without acute inflammation. In case of AKI, hepci-
din rise in serum is caused by increase of TR-Fe 
and IL-6 that induce hepcidin expression, thus it 
can act in preventing iron oxidative damage. But 
why a post-surgically better functioning kidney tu-
bules (not prone to subsequent AKI) do not com-
pletely reabsorb hepcidin and degrade it is still un-
known.
The influence of immunosuppressive 
therapy
Immunosupressive therapy (IS) after renal TX con-
tributes to the development of anemia through 
different mechanisms. Antimetabolites, such as az-
athioprine, mycophenolic acid (MPA) and my-
cophenolate mofetil (MMF), have a direct effect on 
bone marrow cells and their suppression may ag-
gravate anemia (39,56). In a cohort study with 878 
renal transplant recipients it was reported that 
58% of them on MMF were anemic and presented 
with lower GFR than patients not given MMF. A 
possible confounding factor was that all patients 
on treatment with ESA were classified as anemic, 
irrespective of hemoglobin concentrations. Per-
haps those patients would be better classified by 
hemoglobin concentration. The effect of this po-
tential classification error is not large, since only 68 
adults were stimulated by recombinant EPO and 
75% stayed anemic despite therapy (57). In a small-
er study on 170 renal transplant recipients, those 
treated with MMF or MPA showed lower hemo-
globin compared to patients not treated with 
MMF or MPA. Similar observations were found in 
patients treated with mTOR inhibitors sirolimus or 
everolimus, which can cause myelosuppression 
and anemia particularly when administered to-
gether with MMF. Maiorano et al. conducted a 
study that included 42 biopsy-proven chronic allo-
graft nephropathy patients randomized to receive 
cyclosporine or sirolimus. Based exclusively on 
hepcidin results, the authors suggested that siroli-
mus interferes with iron metabolism and that in 
this case PTA does not present the features of in-
flammation-related anemia, since serum hepcidin 
was similar in the two groups after therapy rand-
omization. However, their observation is based 
only on hepcidin, ferritin and transferrin concen-
trations, not on other inflammatory markers, and 
the study in general is of limited power due to a 
small number of patients and the fact that it meas-
ured prohepcidin and not the active hepcidin-25 
(58). Thaunat et al. investigated CRP, IL-6 and IL-10, 
and reported an opinion opposite to Maiorano: 
sirolimus induces a defective IL-10–dependent au-
toregulation of inflammation, thereby inducing 
anemia, in cases of late introduction of sirolimus 
(59). A retrospective study performed on 93 allo-
graft recipients with sirolimus-induced anemia 
and microcytosis showed no impact of MMF on 
the occurrence or severity of PTA (60). In assessing 
the influence of IS therapy on hepcidin anemia af-
ter renal TX first thing that should be made clear in 
future studies is which IS (if any) can be associated 
with subclinical inflammation that could cause a 
rise in hepcidin (and lead to functional iron defi-
ciency and impaired gastrointestinal absorption of 
iron). Hepcidin measurement in such anemic pa-
tients might help prove IS role in PTA pathogenesis. 
This mechanism seems more likely for mTOR inhibi-
tors, at least for now. As far as MMF/MPA therapy is 
concerned, it seems that anemia is caused by IS ef-
fect on bone marrow, rather than the inflammatory 
effect that could cause a hepcidin rise.
Hepcidin determination
The small size of hepcidin and its different iso-
forms made it a challenge to produce a specific 
immunoassay and therefore hepcidin was consid-
ered a hormone very difficult to measure. Radio-
immunoassay (RIA) is very sensitive and specific 
immunoassay method that was first considered 
for hepcidin measurement. It uses a competitive 
principle - radioactive 125I bound to tyrosine or his-
tidine of synthetic hepcidin-25 (in known amount) 
is mixed with serum from patient containing an 
unknown quantity of hepcidin. The radioactive 
and non-radioactive hepcidin molecules compete 
for polyclonal rabbit anti-hepcidin-25 antibody. 
Immunocomplexes are separated using a second-
ary antibody-PEG assisted separation and quanti-
fied by radioactivity measurement. Since this 
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method has been suppressed by non-radioactive 
immunoassays (ELISA), the only commercially 
available RIA test is “Hepcidin-25 RIA kit” (Bachem, 
UK). Manufacturer has declared measurement 
range of 0.1-13 ng/mL, using the hepcidin-25 as 
standard. Ashby et al. evaluated this assay and 
found it to be linear up to 200 ng/mL, with a de-
tection limit of 0.6 ng/mL, intra-assay precision 
7.2% (at 3 ng/mL) and 5.8% (at 35 ng/mL), and in-
ter-assay precision 7.6% (at 3 ng/mL) and 6.7% (at 
35 ng/mL). Analytical recovery was 98% (5 ng/mL) 
and 97% (40 ng/mL). Cross-reactivity with synthet-
ic hepcidin-20 was observed, and it was 9.6% (200 
ng/mL). There was no cross-reactivity with pro-
hepcidin (25). A 10-20% cross-reactivity with hep-
cidin-20 and -22 was found (61).
The first ELISA for serum hepcidin was developed 
and evaluated by Ganz et al. It was a competitive 
assay with biotinylated hepcidin-25 (Intrinsic LifeS-
ciences, La Jolla, CA, USA) as a tracer and a syn-
thetic hepcidin was used for standard curve meas-
urement. No accuracy or recovery data was re-
ported, but intra-assay precision of 5-19% and in-
ter-day precision of 12% was found. Measurement 
range was declared at 5.6 - 4000 ng/mL, but preci-
sion data indicate that the detection limit may be 
closer to 50 ng/mL. The extent of cross-reactivity 
with hepcidin-20 and -22 has not been stated for 
this assay, and should be examined in the future. 
Their evaluation study enrolled 114 healthy volun-
teers and showed a diurnal increase of serum hep-
cidin at noon and 8 p.m. compared with 8 a.m., 
and a transient rise as a response to iron ingestion. 
Using this immunoassay they found normal values 
of hepcidin to be 29 - 254 ng/mL in men and 17 - 
286 ng/mL in women (48). The same ELISA test 
was later reported to have median hepcidin con-
centrations of 73 ng/mL for healthy subjects and 
270 ng/mL for CKD patients. Researchers conclud-
ed that their findings are in agreement with those 
reported by Ashby et al. for hepcidin levels in CKD 
patients using radioimmunoassay (62), which de-
termined normal range for healty subjects at 2 - 56 
ng/mL with median hepcidin concentrations of 11 
ng/mL. In CKD patients, hepcidin concentrations 
ranged from 3 - 153 ng/mL with a median 26.5 ng/
mL (25). Considering the very wide range, the 
method would probably be better suited for hep-
cidin measurement in renal transplant recipients 
and CKD patients rather than healthy subjects, 
since they are expected to have higher hepcidin. 
Precision must be taken into account, considering 
that precision data indicates that the detection 
limit of competitive ELISA could be much higher 
than manufacturer states (50 ng/mL, and not 5.6 
ng/mL), which is in range with hepcidin concentra-
tions expected in healthy subjects. Besides the dif-
ference in calibration, antibody affinity for differ-
ent isoforms, binding to α2-macroglobulin and al-
bumin, circadian rhythm and lack of standardiza-
tion in blood collection may also contribute to 
variations in hepcidin concentration in healthy 
population.
Commercially available kit “Hepcidin-25 (bioac-
tive) ELISA“ (DRG International Inc., Springfield, NJ, 
USA) uses a sandwich principle with monoclonal 
antibodies against hepcidin-25 in serum/plasma, 
with no detectable cross-reactivity to prohepcidin 
and no reports on cross-reactivity to hepcidin-20 
and -22. This presents a problem when measuring 
hepcidin in patients with ESRD since they have 
higher hepcidin-20 and -22 concentrations in se-
rum (63). The manufacturer declares an assay 
range of 0.35 - 80 ng/mL, with possible dilution up 
to 100-fold for hepcidin concentrations higher 
than dynamic range. The mean intra-assay coeffi-
cient of variation (CV) stated is 5.1% and inter-as-
say CV 12.7%. DRG also offers a “Pro-hepcidin ELI-
SA kit” for prohepcidin measurement in serum, 
plasma and homogenisated tissue. Its declared de-
tection range is 3.95 - 1000 ng/mL, and the same 
intra- and inter-assay CV < 10% (http://www.drg-
international.com). These assays have not yet been 
evaluated in the routine clinical setting.
Kulaksiz et al. have also developed an ELISA meth-
od for serum prohepcidin quantification. It uses an 
anti-hepcidin rabbit antibody for prohepcidin and 
N-terminally biotinylated prohepcidin as a com-
petitor and streptavidin-peroxidase to facilitate 
detection. This assay is reported to be very repro-
ducibile and sensitive, but its most important dis-
advantages are the detection of the pro-peptide 
region of hepcidin, the lack of clear correlation 
with active hepcidin-25 and no correlation with 
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iron status markers (e.g. iron, ferritin, transferrin) 
(64-66). 
Mass spectrometry is useful for quantifying small 
molecules and peptides. The molecule undergoes 
ionization and fragmentation and the generated 
charged fragments are recognized and measured 
by their mass-to-charge ratios. For hepcidin meas-
urement several technological approaches have 
been used – surface enhanced laser desorption-
time of flight mass spectrometry (SELDI-TOF MS), 
MALDI-TOF MS and liquid chromatography tan-
dem mass spectrometry (LC MS/MS). The main ad-
vantages of these methods are the separation of 
hepcidin isoforms and quantification of only hep-
cidin-25 without interferences of hepcidin-20 and 
-22, and quantification can be done in serum and 
urine samples. Using SELDI-TOF MS with desAsp-
hepcidin (hepcidin-24) as internal standard, Swin-
kels et al. showed good precision (< 10% CV), but a 
difference in desAsp-hepcidin and hepcidin-25 
binding properties that may indicate that this is 
not the best choice of internal standard (49). Oth-
ers used isotope-labeled hepcidin as internal 
standard in SELDI-TOF MS with good intra-day (< 
10%) and inter-day (< 20%) precision, as well as 
limit of detection of 10 ng/mL (67). Those studies 
had no accuracy and recovery data presented. Kem-
na et al. evaluated SELDI-TOF MS for quantification 
of hepcidin isoforms in serum and urine in 73 sub-
jects with different iron status, from iron deficiency 
to hereditary hemochromatosis. They used synthet-
ic human hepcidin-25 for calibration. Interestingly, 
they found all three isoforms in urine, but no hepci-
din-22 in serum, which supports the evidence that 
hepcidin-20 and -25 are produced in hepatocytes 
and released in blood stream, while hepcidin-22 is a 
urinary degradation product of hepcidin-25 (68). 
MALDI-TOF MS with isotope-labeled hepcidin as in-
ternal standard, but only for urine samples, because 
serum samples displayed poor peak resolution. This 
method shows limit of detection 1 - 300 nmol/L 
(2.8 - 836.9 ng/mL) with intra-assay CV 12.1% and 
inter-assay precision 13.2% (66). 
LC MS/MS was first used in hepcidin quantification 
by Murphy et al., after reverse solid phase extrac-
tion. Calcitonine gene-related peptide was used as 
internal standard. The method showed good ac-
curacy and precision and a limit of quantification 
of 1.0 ng/mL (69). Recent methods that used syn-
thetic stable isotope-labeled hepcidin as internal 
standard were in concordance, with limits of quan-
tification from 1.1 - 2.5 ng/mL and upper limits be-
tween 159 and 500 ng/mL. They showed good in-
ter-day precision (CV < 10%) (70,71). Li et al. used 
60 control samples and 50 CKD patients, and 
found hepcidin means for them to be 10 ng/mL 
and 99 ng/mL, respectively. This method was vali-
dated to FDA criteria for bioanalytical assays (70). 
Study that used standardized serum and urine 
hepcidin sampling showed reference values in 
healthy subjects to be 0.77 to 200 nmol/L for urine, 
when measured by LC-MS/MS, with a coefficient of 
renal excretion ranging from 0.1 to 16.4%. The se-
rum reference values were 0.48 - 100 nmol/L, in 
agreement with that obtained by Li et al. (72). A 
short overview of hepcidin measurement methods 
and their characteristics is presented in Table 3.
Studies evaluating hepcidin concentrations in CKD 
found elevated concentrations in HD patients 
compared with healthy volunteers, but absolute 
values of serum hepcidin varied up to 10-fold de-
pending on the assay (25,48,62,66,73,74). On the 
other hand, a few found hepcidin concentrations 
to be lower after HD (63,75). These contradictory 
results must be researched in the future and the 
effect of HD should also be taken into account. 
Also, an ELISA method should be further improved 
to detect only free hepcidin-25. In fact, the lack of 
standardization in hepcidin testing, as well as the 
lack of specificity for free, total or bound hepcidin 
(i.e. to α2-macroglobulin), have led Kroot et al. to 
initiate a round robin on hepcidin serum and uri-
nary quantification. They sent 12 replicates of sam-
ples, 8 urine samples and 7 plasma pool samples 
with a wide range of hepcidin from healthy sub-
jects and added synthetic hepcidin-25, to be 
measured in various laboratories by 8 different 
methods (competitive RIA, MALDI-TOF MS, two 
SELDI-TOF MS methods, two LC-MS/MS and two 
competitive ELISA methods). ELISA methods 
showed higher hepcidin concentrations compared 
to LC-MS/MS method (in urine hepcidin means up 
to 11-fold and SD up to 27-fold and in serum hep-
cidin means up to 8-fold and SD up to 30-fold). An-
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alytical variations for these methods were found 
to be generally low and similar for all methods 
(76). This huge difference in ELISA and LC-MS/MS 
hepcidin measurement could be due to the fact 
that ELISA lacks the sensitivity to distinguish hep-
cidin-25 from hepcidin-20 and -22. Therefore, in 
case of hepcidin determination introduction in 
routine laboratory practice, patients should be 
monitored exclusively using the same, possibly 
standardized, method. Before commercial hepci-
din ELISA can be implemented in routine labora-
tory practice, cross reactivity for hepcidin-20 and 
-22 should be evaluated by an independent party. 
If MS based methods will become routinely used, 
despite their expensive and time-consuming na-
ture, a few criteria should be agreed upon: a stand-
ard internal standard, commutable calibrator that 
mimics human matrix and adequate quality con-
trol. In light of hepcidin measurement standardi-
zation we strongly recommend this be addressed 
in future studies.
Potential therapeutic use of hepcidin
Hepcidin agonists and antagonists have been de-
signed in order to modulate iron metabolism. 
Hepcidin agonists are designed to treat iron over-
load in hereditary hemochromatosis and thalas-
semia in order to avoid currently used treatment 
with phlebotomies and their side effects. Treat-
ments like injection of BMP6, oligonucleotids or 
small interfering RNA against Tmprss6 mRNA and 
minihepcidin (PR65) showed results in decreasing 
hepcidin concentrations and iron overload in 
mouse models of hereditary hemochromatosis 
and/or thalassemia. Minihepcidin is a lipophilic 
Method Sensitivity (ng/mL) Specificity Main feature Limitation
RIA
(Hepcidin-25 RIA Kit, 
Bachem) (61)
0.1 10 - 20% cross reactivity with hepcidin-20 and -22
High sensitivity;




(Ganz et al .) (48) 5.6 
Cross reactivity with 
hepcidin-20 and -22 not 
evaluated
Wide measurement range (up 
to 4 μg/mL)
High imprecision at < 
50 ng/mL (not suitable 
for healthy subjects)
Hepcidin-25 (bioactive) 
ELISA (DRG) (http://www .
drg-international .com)
0.35 
No detectable cross reactivity 
with prohepcidin (0.04%);
No data on cross reactivity with 
hepcidin-20 and -22




SELDI-TOF MS (67) 10 Specific for hepcidin-25
In agreement with 
competitive ELISA (Ganz 
et al.) for mean hepcidin 
concentrations in healthy 
subjects
No standardization; no 
internal standard
MALDI-TOF MS (66) 2.8 Specific for hepcidin-25
High accuracy (90–110% 
recovery);




LC-MS/MS (70) 2.5 Specific for hepcidin-25
Good inter-assay precision 
(CV < 10%);
Validated to FDA criteria
Matrix of standards 
does not mimic 
human serum (rabbit 
serum used)
RIA – radioimmunoassay; CV – coefficient of variation; ELISA – enzyme-linked immunosorbent assay SELDI-TOF MS – surface 
enhanced laser desorption-time of flight mass spectrometry; MALDI-TOF MS – matrix assisted laser desorption ionization-time of 
flight mass spectrometry; LC MS/MS - liquid chromatography tandem mass spectrometry.
Table 3. Comparison of methods for hepcidin determination.
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peptide that contains 9 aa of the hepcidin’s N-ter-
minus which are important for its activity (77). MT-
2, as the strongest inhibitor of hepcidin, has been 
targeted by antisense oligonucleotides against its 
mRNA (Tmprss6 mRNA) or small interfering RNA 
(siRNA) against Tmprss mRNA. Injection of sHJV 
and HJV antisense oligonucleotides selectively in-
hibited BMP induction of hepcidin expression (78). 
The search for optimal treatment for anemia of 
chronic disease gave even more candidates that 
showed successful in decreasing hepcidin. Hepa-
rin, and his subsequently developed non-antico-
agulant forms that bind to BMPs, showed promise 
in blocking hepcidin transcription and decreasing 
hepcidin plasma concentration after intravenous 
injection in mice. Similar approaches have been 
tried with injections of dorsomorphin and its deri-
vate LDN-193189, which bind to BMP-R and act as 
inhibitors of BMP-mediated hepcidin transcription 
pathway (78,79). Injections of BMP and IL-6 had 
showed the same effect, but to a different extent - 
injection of BMP-2, -4, -5, -6, -7 and -9 showed a 
hepcidin mRNA increase up to 1000-fold, while 
IL-6 initiated an increase of only 3.3-fold (80). Anti-
hepcidin was used for hepcidin neutralization and 
hepcidin mRNA suppression in a mouse model of 
disease. This treatment was able to increase iron 
and hemoglobin and overcome anemia of chronic 
disease (81). Treatment with antibodies such as 
anti–IL-6 receptor antibody (tocilizumab) was the 
first potential therapeutic tested on humans and it 
improved anemia of inflammation in multicentric 
Castleman disease (82,95). Spiegelmer NOX-H94, 
non-immunoreactive L-oligoribonucleotide that 
binds human hepcidin with high affinity (83), and 
anticalins that bind human hepcidin were used to 
block hepcidins target ferroportin or hepcidin itself. 
Anti-ferroportin antibodies and anticalin PRS-080 
are in phase I of clinical trials (84,85). Lowering 
HAMP expression by these or similar mechanisms in 
humans could increase iron release form stores and 
help with recovery of anemia patients (Table 4).
Final considerations
This review is the first one that focuses on hepci-
din in renal TX recipients. Specific topics regarding 
management of renal transplant recipients have 
been addressed, such as IS therapy influence on 
PTA and hepcidin, and the role of hepcidin in re-
sistance to ESA. We addressed hepcidin at a mo-
lecular, biochemical and clinical level. In inflamma-
tion hepcidin gene is induced by IL-6 (via JAK2/
STAT3 signal pathway), as well as BMP6 (via pS-
MAD1/5/8 and SMAD4 pathway) (10). The resulting 
effect is the unavailability of iron supplies to mi-
croorganisms with high-affinity iron-binding si-
derophores that make them able to use iron from 
the host’s transferrin. mHJV was identified as a 
BMP co-receptor in hepcidin’s expression signal-
ing pathway. MT2 is a hepcidin suppressor, as it 
binds mHJV on hepatocytes and stops its BMP co-
receptor activity. Homozygotes or combination 
heterozygotes mutations of mHJV in humans 
markedly reduce hepcidin expression and cause 
juvenile hemochromatosis type 2A, whereas mu-
tations in HAMP cause juvenile hemochromatosis 
type 2B (87). Besides hemochromatosis and thalas-
semia, the hereditary causes for hepcidin down-
regulation, later studies identified hypoxia-induci-
ble factors - HIF-1α and HIF-2α as a possible down-
regulators of hepcidin in hypoxia. Some research-
ers found that HIF-1α subunit binds to enhancer 
element of EPO gene activating its transcription, 
but also seems to bind to enhancer element of 
HAMP gene and down-regulates it (21). Others 
claim that HIF-2α exclusively regulates EPO gene, 
based on exspresion studies on hepatocytes and 
immunohistochemical studies that localized Hif-2α 
but not Hif-1α to EPO-producing renal cells (88). 
This down-regulation mechanism is still controver-
sial, since there have been some studies claiming 
that only erythropoietic activity suppresses hepci-
din expression, rather than it being regulated by 
HIFs in hypoxia (26,27). Molecular mechanism for 
hepcidin plasma increase in hypoxia or anemia 
should be further investigated. Other potential 
down-regulators as GDF15 and TWSG1 also seem 
promising in further clarifying hepcidin regula-
tion. They are released by erythroid precursors in 
some iron-loading anemias. TWSG1 expression is 
increased in thalassemic mice during early eryth-
roblast maturation (suggested mechanism is inac-
tivation of BMP/SMAD activation of HAMP). High 
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GDF15 concentrations can suppress HAMP in cell 
models, but the underlying molecular mechanism 
has not yet been characterized (89). A potential 
up-regulator activin B has been found to have ef-
fect on SMAD-mediated regulation of HAMP tran-
scription in hepatoma-derived cell cultures but 
that is jet to be confirmed in vivo (90).
Up to 90% of circulating hepcidin is bound to α2-
macroglobulin, and this complex was shown to re-
duce iron concentrations to a significantly greater 
extent than free hepcidin. It is argued that the rea-
son is slower hepcidin urine excretion, but this re-
mains to be confirmed in humans (8). In renal 
transplant recipients this could be of great signifi-
cance, since their renal excretion is limited by graft 
function. In case of degrading graft function plas-
ma hepcidin elevation could theoretically contrib-
ute to PTA and resistance to ESA treatment, as it 
was shown in CKD. EPO has been identified as a 
hepcidin suppressor, but it is unclear if it is ineffec-
tive in hepcidin suppression in ESA-resistant PTA 
or his suppression is simply not adequate enough 
compared to other active hepcidin up-regulating 
mechanisms. In renal recipients with worsening 
graft function hepcidin is expected to be up-regu-
lated because of uremia and/or subclinical inflam-
mation (by IL-6 activation of JAK2/STAT3-mediated 
HAMP transcription). Another reason for plasma 
hepcidin increase is iron substitution therapy after 
renal TX that has a positive effect on HAMP tran-
scription by BMPs. It also increases TR-Fe displace-
ment of HFE from TRF1 and formation of HFE-
TRF2-mHJV supercomplex that induces HAMP. 
Could that lead to higher hepcidin serum concen-
tration and cause PTA? Could it be in that extent 
that it could become a marker of kidney function 
or predictor of PTA? At this point of research and 
with different measurements challenges hepcidin 
faces it is still too early to say. 








BMP-R DorsomorphinInjection of LDN193189
Decrease in hepcidin
Decrease in hepcidin
HJV Injection of sHJVHJV antisense oligonucleotides
Decrease in hepcidin
Decrease in hepcidin
MT-2 mRNA (Tmprss6 mRNA) Tmprss6 mRNA antisense nucleotidessiRNA against Tmprss6 mRNA
Increase in hepcidin
Increase in hepcidin
STAT3 Phosphorylation inhibitor AG490 Decrease in hepcidin
IL-6-R Anti-IL-6-RInjection of IL-6
Decrease in hepcidin
Increase in hepcidin
Ferroportin Minihepcidin (PR65)Anti-ferroportin antibodies
Increase in hepcidin
Decrease in hepcidin
Hepcidin Anti-hepcidin speigelmer NOX-H94Anticalin PRS-080
Decrease in hepcidin
Decrease in hepcidin
EPO Injection of EPO Decrease in hepcidin
*The  substances listed above were tested only on animal models (murine, cynomolgues monkey and zebrafish), hepatoma cell 
cultures (HepG2 cells) or are in the beginning of clinical trials. Only anti-IL-6 was tested on humans in a multicentric study. 
BMP6 – bone morphogenic protein 6; anti-BMP6 – antibody against BMP6; BMP-R – bone morphogenic protein receptor; sHJV – 
solubile hemojuvelin; MT-2 – matriptase 2; Tmprss6 - gene for MT-2; siRNA – small interfering RNA; STAT3 – signal transducer and 
activator of transcription 3; IL-6-R – interleukin 6 receptor; anti- IL-6-R – antibody against interleukin 6 receptor.
Table 4. Potential therapeutics for hepcidin regulation and their effect (15, 28, 77-86).
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Hepcidin has been shown to be a good marker of 
iron status after renal TX and it is superior to cur-
rent markers of iron homeostasis (iron, transferin 
saturation and solubile transferin receptor) (45). 
Many studies have reported considerable hepci-
din and ferritin asociation in anemia (39,47,58,91), 
but with one important advantage of hepcidin – 
instead of reflecting how much iron is circulating 
or stored, it is the most sensitive indicator of iron 
absorption and reflects how much iron is accessi-
ble under current conditions (inflammation, iron 
concentration, anemia and hypoxia). Because hep-
cidin serum concentration is regulated by all of 
these processes, hepcidin gives a better insight 
into complex iron homeostasis. Since hepcidin 
acts in preventing iron oxidative damage in in-
flammation (as seen in AKI), its’ use should be lim-
ited to non-inflammatory states (similar to other 
acute phase proteins), at least when one is assess-
ing renal TX recipients for possible chronic rejec-
tion (recipients without subclinical inflammation 
can be selected by determining high sensitive 
CRP). On the other hand, researchers that studied 
hepcidin after cardiac surgery found increased 
urine hepcidin protective for AKI (52). This justifies 
further research on inflammation induced local 
production of hepcidin in kidneys and possibly 
designing a study that accesses diagnostic abilities 
of urine hepcidin in predicting AKI in renal TX re-
cipients.
In addition to its correlation with ferritin, hepcidin 
correlates with creatinine, total protein and eGFR 
(calculated by MDRD) in patients after renal TX, 
but only ferritin and eGFR could be used as predic-
tors of hepcidin (47). It is clear that high hepcidin 
concentration contributes to PTA, but additional 
research is needed to determine if hepcidin can be 
used to predict ESA resistance in renal TX recipi-
ents. Since iron and recombinant EPO are often 
used for PTA treatment, future studies will also 
have to assess the effect of each of these thera-
peutics on hepcidin regulation, since high iron in-
duces HAMP expression and EPO decreases it. 
Research on effect of IS therapy on hepcidin is lim-
ited to a single study by Maiorano et al. that rand-
omized patients to receive sirolimus and cyclo-
sporine and showed no difference in serum hepci-
din concentrations in patient groups (58). This is 
confounding because sirolimus has been argued 
to induce PTA. Possible reason for contradictory 
results in these studies is the difference in immu-
nological risk for transplant recipients and subse-
quent difference in dose adjustment in each study. 
Inadequate level of immunogical suppression 
achieved by sirolimus could result in inadequate T 
and B-cell suppression and larger than necessary 
production of IL-6 in B-cells. This IL-6 could theo-
retically induce HAMP transcriprion and hepcidin. 
Other IS that have been associated with a higher 
incidence of anemia after renal TX are azathio-
prine, MPA and MMF (92,93), and their effect on 
hepcidin concentration should be investigated in 
future research.
Measurement of hepcidin should be standardized, 
since immunochemical and MS methods show 
non comparable hepcidin results (up to 10-fold 
higher in healthy subjects measured by immuno-
chemical methods) (25,48,62,66,73,74). MS meth-
ods show higher precision and specificity to hepci-
din-25, but lack of universal internal standard. In 
order to be able to compare hepcidin results from 
MS methods a universal internal standard is need-
ed. Calibrators used in MS methods should mimic 
human serum and urine. Cross reactivity between 
hepcidin-25 and hepcidin-20 and -22 should be re-
duced using more specific antibodies in immuno-
chemical tests. Most researchers agree that meas-
urement of prohepcidin cannot be a substitute for 
determination of hepcidin because there is no 
clear relationship or correlation between serum 
concentrations of prohepcidin and hepcidin (6,94).
Various innovative potential therapeutics, that de-
crease or increase hepcidin concentration, are cur-
rently being tested. Anti-ferroportin antibodies 
and anticalin PRS-080 are in phase I of clinical trials 
(84,85), whereas anti–IL-6 receptor antibody (tocili-
zumab) was shown to improve anemia of inflam-
mation in multicentric Castleman disease (82,95). If 
these substances prove safe for human use and 
useful in decreasing plasma hepcidin the next step 
should be testing them in a multicentric rand-
omized trial on patients with PTA to determine if 
they are able to reduce ESA-resistance after renal 
TX. 
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Conclusion
Hepcidin is a central regulatory protein of iron ho-
meostasis and is greatly influenced by immunity. 
High hepcidin concentrations reflect the status of 
chronic (in CKD) as well as acute inflammation (in 
AKI), but the specific mechanisms involved in hep-
cidin increase are different. CKD is associated with 
accumulation of hepcidin in serum witch contrib-
utes to anemia and ESA. Hepcidin is the most sen-
sitive marker of iron absorption and the only mark-
er that reflects iron availability. Because of those 
characteristics it is extensively researched as a 
therapeutic target, both in anemia and iron over-
load disease.
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